PubRank

Lisa D Edwards

Author PubWeight™ 53.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011 5.69
2 Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010 5.17
3 Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2012 3.44
4 Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012 2.52
5 Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006 2.49
6 Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 1.99
7 A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2011 1.98
8 Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol 2011 1.88
9 Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013 1.79
10 Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015 1.72
11 Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013 1.66
12 Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003 1.54
13 Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010 1.51
14 Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006 1.44
15 COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011 1.43
16 Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013 1.41
17 Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med 2010 1.30
18 Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2011 1.28
19 Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011 1.23
20 Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2011 1.23
21 Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014 1.20
22 Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011 1.11
23 Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol 2002 1.03
24 CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res 2013 0.91
25 Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005 0.90
26 Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann Allergy Asthma Immunol 2003 0.84
27 Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. Respir Med 2013 0.83
28 Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respir Med 2011 0.82
29 Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD. COPD 2011 0.82
30 Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2014 0.78
31 Reply: minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med 2013 0.77
32 Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am J Med 2002 0.77
33 Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respir Med 2010 0.76
34 Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Curr Med Res Opin 2009 0.75